These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12457422)

  • 1. Returns on research and development for 1990s new drug introductions.
    Grabowski H; Vernon J; DiMasi JA
    Pharmacoeconomics; 2002; 20 Suppl 3():11-29. PubMed ID: 12457422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The distribution of sales revenues from pharmaceutical innovation.
    Grabowski HG; Vernon J
    Pharmacoeconomics; 2000; 18 Suppl 1():21-32. PubMed ID: 11151306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The opportunity cost of capital: development of new pharmaceuticals.
    Chit A; Chit A; Papadimitropoulos M; Krahn M; Parker J; Grootendorst P
    Inquiry; 2015; 52():. PubMed ID: 25933615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Returns to R&D on new drug introductions in the 1980s.
    Grabowski HG; Vernon JM
    J Health Econ; 1994 Dec; 13(4):383-406. PubMed ID: 10140531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
    Tay-Teo K; Ilbawi A; Hill SR
    JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical R&D performance by firm size: approval success rates and economic returns.
    DiMasi JA
    Am J Ther; 2014; 21(1):26-34. PubMed ID: 23344103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
    Grabowski H
    Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decline in economic returns from new drugs raises questions about sustaining innovations.
    Berndt ER; Nass D; Kleinrock M; Aitken M
    Health Aff (Millwood); 2015 Feb; 34(2):245-52. PubMed ID: 25646104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do companies in the pharmaceutical supply chain earn excess returns?
    Sood N; Mulligan K; Zhong K
    Int J Health Econ Manag; 2021 Mar; 21(1):99-114. PubMed ID: 33394339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial returns on R&D: looking back at history, looking forward to adaptive licensing.
    Scannell JW; Hinds S; Evans R
    Rev Recent Clin Trials; 2015; 10(1):28-43. PubMed ID: 25925881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Security market reaction to FDA fast track designations.
    Anderson CW; Zhang Y
    J Health Care Finance; 2010; 37(2):27-48. PubMed ID: 21294437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies.
    Hwang TJ
    PLoS One; 2013; 8(8):e71966. PubMed ID: 23951273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
    Prasad V; Mailankody S
    JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research and development costs for drugs.
    Riggs TL
    Lancet; 2004 Jan; 363(9404):184. PubMed ID: 14738789
    [No Abstract]   [Full Text] [Related]  

  • 16. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategic options for brand-name prescription drugs when patents expire.
    Mehta SC; Mehta SS
    Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.
    Kesselheim AS; Rome BN; Sarpatwari A; Avorn J
    Health Aff (Millwood); 2017 Feb; 36(2):362-370. PubMed ID: 28100464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trajectories of Injectable Cancer Drug Costs After Launch in the United States.
    Gordon N; Stemmer SM; Greenberg D; Goldstein DA
    J Clin Oncol; 2018 Feb; 36(4):319-325. PubMed ID: 29016226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical research and development.
    McKercher PL
    Clin Ther; 1992; 14(5):760-4; discussion 759. PubMed ID: 1468093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.